29 August 2019
EMA/476687/2019
EMEA/H/C/003768

Public statement

Daklinza

Expiry of the marketing authorisation in the European Union

The marketing authorisation for Daklinza (daclatasvir) expired on 26 August 2019 following the decision of the marketing authorisation holder, Bristol-Myers Squibb Pharma EEIG, not to apply for a renewal of the marketing authorisation for commercial reasons.

Daklinza was granted marketing authorisation in the European Union (EU) on 22 August 2014 for the treatment of chronic hepatitis C virus (HCV) infection in adults. The marketing authorisation was valid for 5 years.

The European Public Assessment Report (EPAR) for Daklinza will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union